Insulin and insulin-like growth factor pathway, a new targeted therapy in oncology;La vía de la insulina y el factor de crecimiento similar a la insulina, una nueva diana terapéutica en oncología

Anales del Sistema Sanitario de Navarra

Volumn 32, Issue SUPPL.3, 2009, Pages 413-421

  Bosch Barrera, Joaquim ^a   Hernandez A ^a   Abella, L E ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Insulin receptor; Insulin receptor related receptor; Insulin like growth factor I; Insulin like growth factor II

Indexed keywords

HUMANS; INSULIN; INSULIN ANTAGONISTS; NEOPLASMS; SIGNAL TRANSDUCTION; SOMATOMEDINS;

HYPERGLYCEMIC AGENT; INSULIN; SOMATOMEDIN;

ANTAGONISTS AND INHIBITORS; HUMAN; NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

EID: 77952044986     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Chan SJ, Steiner DF. Insulin through the ages: phylogeny of a growth promoting and metabolic regulatory hormone. American Zoologist 2000; 40: 213-222.
2. Dong MQ, Venable JD, Au N, Xu T, Park SK, Cociorva D et al. Quantitative mass spectrometry identifies insulin signaling targets in C. elegans. Science 2007; 317: 660-663.
3. Toyoshima Y, Monson C, Duan C, Wu Y, Gao C, Yakar S et al. The role of insulin receptor signaling in zebrafish embryogenesis. Endocrinology 2008; 149: 5996-6005.
4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
5. Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26: 263-274.
6. Raju TN. A mysterious something: The discovery of insulin and the 1923 Nobel Prize for Frederick G. Banting (1891-1941) and John J.R. Macleod (1876-1935). Acta Paediatr 2006; 95: 1155-1156.
7. Salmon WD Jr, Daughaday W. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-836
8. Laron Z. The somatostatin-GHRH-GH-IGF-I axis. En: Merimee T, Laron Z, eds. Growth hormone, IGF-I and growth: new views of old concepts. Modern endocrinology and diabetes, Vol. 4. London-Tel Aviv: Freund Publishing House Ltd, 1996: 5-10.
9. Berg U, Bang P. Exercise and circulating insulin-like growth factor I. Horm Res 2004; 62 Suppl. 1: 50-58.
10. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
11. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-649.
12. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 5563-5568.
13. Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature 2008; 454: 345-349.
14. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13: 671-686.
15. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114: 23-37.
16. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays 2004; 26: 1351-1362.
17. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995; 11: 447-449.
18. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
19. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A 1976; 73: 4536-4540.
20. Heuson JC, Legros N, Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res 1972; 32: 233-238.
21. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987; 38: 223-230.
22. Myal Y, Shiu RP, Bhaumick B, Bala M. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 1984; 44 (12 Pt 1): 5486-5490.
23. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993; 90: 11217-11221.
24. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst 1999; 91: 620-625.
25. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000: 345-349.
26. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63: 4384-4388.
27. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999; 85: 1284-1292.
28. Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004; 64: 6252-6258.
29. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006; 98: 315-327.
30. Lacy MQ, Alsina M; Fonseca R, Paccagnella ML, Melvin CL, Yin D et al. Phase I, Pharmacokinetic and pharmacodynamic study of the antiinsulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
31. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
32. Karp DD, Paz-Ares LG, Novellos S, Haluska P, Garland L, Cardenal F et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. J Clin Oncol 2008; 26 (Suppl), 8015.
33. Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007 25 (Suppl) 3002.
34. Moreau P, Hulin C, Facon T, Boccadoro M, Mery-Mignard D, Deslandes A et al. Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Proceedings of ASH 2007, abstract 1166.
35. Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R antagonist, in patients with advanced solid tumor. J Clin Oncol 2008; 26 (Suppl), 3582.
36. Hidalgo M, Tirado Gómez M, Lewis N, Vuky JL, Taylor G, Hayburn JL et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008; 26 (Suppl), 3520.
37. Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dia C et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. J Clin Oncol 2007; 26 (Suppl), 3590.
38. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Rev Cancer 2004; 4, 505-518.
39. del Rincon JP, Lida K, Gaylinn BD, McCurdy CE, Leitner JW, Barcour LA et al. Growth hormone regulation of p85 expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007; 56, 1638-1646.
40. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66: 362-371.
41. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mark G et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158-2167.
42. Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Langley DR, Sang X et al. Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors. Bioorg Med Chem Lett 2008; 18: 4075-4080.
43. Mulvihill MJ, Ji QS, Coate HR, Cooke A, Dong H, Feng L et al. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulinlike growth factor-I receptor (IGF-IR) inhibitors. Bioorg Med Chem 2008; 16: 1359-1375.
44. Hofmann F, Garcia-Echeverría C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 2005; 10: 1041-1047.
45. Vasilcanu R, Vasilcanu D, Roserngren L, Natalishvili N, Sehat B, Yin S et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and b-arrestin1. Oncogene 2008; 27: 1629-1638.
46. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, DePinho RA et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-1646.
47. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812.
48. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273.